First Drug Approved for Marginal Zone Lymphoma First Drug Approved for Marginal Zone Lymphoma

Ibrutinib is the first drug to be specifically approved for marginal zone lymphoma, which accounts for about 12% of all non-Hodgkin ’ s lymphomas.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news